Related Experiment Video
Updated: Jun 9, 2025
09:09
Dissecting the Non-human Primate Brain in Stereotaxic Space
Published on: July 16, 2009
10.1K
Brain aging and Alzheimer's disease, a perspective from non-human primates
1Department of Pathology and Experimental Therapeutics, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain.
Aging
|October 30, 2024
Summary
Human brain aging is unique, featuring early tau pathology and later beta-amyloid deposition, unlike non-human primates. This leads to more severe cognitive decline and proteinopathies in humans.
Area of Science:
- Neuroscience
- Comparative Biology
- Primatology
Background:
- Brain aging exhibits distinct neuropathological changes across primate species.
- Non-human primates (macaques, baboons, apes) show beta-amyloid deposition but limited tau pathology.
- Human brain aging is characterized by early tau pathology and later beta-amyloid accumulation.
Purpose of the Study:
- To compare brain aging processes between humans and non-human primates.
- To identify key differences in neuropathology and cognitive decline.
- To understand the unique aspects of human brain aging.
Main Methods:
- Comparative analysis of neuropathological hallmarks in aged human and non-human primate brains.
- Review of existing literature on primate brain aging and associated pathologies.
- Correlation of neuropathology with observed cognitive function.
Main Results:
- Non-human primates exhibit diffuse senile plaques (SPs) and cerebral beta-amyloid angiopathy (CAA), with rare tau pathology.
- Human brain aging involves early neurofibrillary tangles (NFTs) and paired helical filaments (PHFs) in specific brain regions, followed by beta-amyloid deposition.
- Humans show a higher prevalence of severe cognitive impairment, Alzheimer's-type dementia, and specific proteinopathies (TDP-43, Lewy bodies, argyrophilic grains) absent in non-human primates.
Conclusions:
- Human brain aging is significantly different from that of non-human primates, particularly in the timing and type of proteinopathies.
- Humans represent an exception among primates regarding the severity and extent of age-related brain damage.
- These differences highlight unique evolutionary trajectories in human neurobiology and aging.
More Related Videos
Related Concept Videos
01:26Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
01:26Aging
37
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
37
03:03Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165